Identification of endogenous normalizers for serum MicroRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer

We read with great interest the article entitled ‘‘Ethnic Differences in Viral Dominance Patterns in Patients with Hepatitis B Virus and Hepatitis C Virus Dual Infection,’’ recently published by Nguyen et al. in this journal. The study was designed to evaluate and compare the demographic, clinical, and viral characteristics of multiethnic patients infected by hepatitis virus admitted at two large liver centers in the United States. The investigators defined the study design as a matched case-control study, in which the case group included patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection, and the control group comprised patients with HBV monoinfection. However, in our opinion, there is an important methodological issue in the reported data: The main conclusion of the article was not about the comparison between cases and controls, but rather it underscored a secondary analysis with cases only in which ethnic differences were examined in terms of viral dominance patterns among HBV and HCV dual-infected patients. It is our opinion that the investigators deviated from the scope of the case-control study originally proposed, because it is clear that the investigation was not delineated to test the hypothesis that ended up becoming the core conclusion, including the title of the article. Therefore, the investigators’ conclusions regarding viral dominance were not consistent with the a priori study aims proposed.

[1]  M. Manns,et al.  HEV-specific T-cell responses are associated with control of HEV infection , 2012 .

[2]  Jonathan Moggs,et al.  Circulating microRNAs as potential markers of human drug‐induced liver injury , 2011, Hepatology.

[3]  T. Berg,et al.  Retreatment with telaprevir combination therapy in hepatitis C patients with well‐characterized prior treatment response , 2011, Hepatology.

[4]  B. Pearlman,et al.  The IL-28B Genotype Predicts Which Slow-Responding Hepatitis C-Infected Patients Will Benefit from Treatment Extension , 2011, The American Journal of Gastroenterology.

[5]  E. Keeffe,et al.  Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection , 2011, Hepatology.

[6]  J. Ellinger,et al.  Circulating microRNAs (miRNA) in serum of patients with prostate cancer. , 2011, Urology.

[7]  Jean-Michel Pawlotsky,et al.  Treatment failure and resistance with direct‐acting antiviral drugs against hepatitis C virus , 2011, Hepatology.

[8]  E. Li,et al.  Serum and urinary free microRNA level in patients with systemic lupus erythematosus , 2011, Lupus.

[9]  Feng-jun Wang,et al.  Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. , 2010, Gynecologic oncology.

[10]  Yue Wang,et al.  Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. , 2010, Clinical chemistry.

[11]  L. Rostaing,et al.  Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. , 2010, Gastroenterology.

[12]  M. Volk,et al.  A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  Frank Speleman,et al.  A novel and universal method for microRNA RT-qPCR data normalization , 2009, Genome Biology.

[14]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[15]  Brian L. Pearlman,et al.  Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders , 2007, Hepatology.

[16]  L. Smeeth,et al.  Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading , 1999, BMJ.